Literature DB >> 1541043

The antiatherogenic effects of antihypertensive drugs: experimental and clinical evidence.

A Zanchetti1.   

Abstract

The question whether some classes of antihypertensive drugs have an antiatherogenic action independent of the antihypertensive one has been investigated through a large series of experimental studies; on the other hand, clinical evidence is still rather scanty. Most experimental investigations have shown a significant antiatherogenic action of the antihypertensive compounds, but only when the drug is administered simultaneously with the atherogenic stimulus (mostly cholesterol feeding). When the drug is administered weeks or months after the beginning of atherosclerosis (as in the Watanabe heritable hyperlipemic rabbit), no antiatherogenic effect has been shown, with a single exception. Although the most numerous data available are on calcium antagonists, almost all antihypertensive classes tested have shown some favorable effect on some experimental model. The few clinical studies completed so far as on coronary patients; they have provided arteriographic evidence that various calcium-antagonists have little effect on well-developed lesions and display a beneficial action on new or early lesions only. Ultrasound studies are now underway to compare the effects of calcium-antagonists and diuretics on asymptomatic carotid atherosclerotic lesions in hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541043     DOI: 10.3109/10641969209036190

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  3 in total

Review 1.  The antiatherogenic effects of antihypertensive treatment: trials completed and ongoing.

Authors:  A Zanchetti
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

2.  Simvastatin combined with nifedipine enhances endothelial cell protection by inhibiting ROS generation and activating Akt phosphorylation.

Authors:  Xiao-niao Chen; Jun Xu; Zhe Feng; Ming Fan; Jing-yao Han; Zhuo Yang
Journal:  Acta Pharmacol Sin       Date:  2010-06-21       Impact factor: 6.150

Review 3.  Choosing the right ACE inhibitor. A guide to selection.

Authors:  G Leonetti; C Cuspidi
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.